Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia
Model scores of the 29,894 trials active now.
Model score 11% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 18% of the time (243 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Terminated.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: schizophreniadouble blindonsetplacebosymptoms
Phrases that lowered it: participantsweeksnasaltumorssocial -
Has a data monitoring committee: not given (lowers risk) · Design
-
Phase: 1/2 (raises risk) · Design
-
Sponsor's past termination rate: 6.8% (lowers risk) · Sponsor's track record
-
Maximum age: 99 (lowers risk) · Who can join
-
Disease area, cancer: No (lowers risk) · Disease area
-
Drug's FAERS reports with a death: 8.1% (lowers risk) · Drug's FDA history
-
Design: parallel (raises risk) · Design
-
Blinding: not given (lowers risk) · Design
-
Sponsor's past trials: 73 (lowers risk) · Sponsor's track record
-
Disease area, psychiatry: Yes (raises risk) · Disease area
-
Primary purpose: treatment (raises risk) · Design
-
Collaborators: 0 (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 1/2 (typical: 2)
- Number of arms
- not given (typical: 2)
- Allocation
- randomized
- Design
- parallel
- Primary purpose
- treatment
- Blinding
- not given (typical: none)
- Has a data monitoring committee
- not given (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 0
- Keywords listed
- 3 (typical: 1)
Who can join
- Minimum age
- 10 (typical: 18)
- Maximum age
- 99 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- government (typical: academic or other)
- Sponsor's past trials
- 73 (typical: 32)
- Sponsor's past termination rate
- 6.8% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 6 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 1
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 519 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 71 (typical: 412.5)
- Drug's FAERS reports marked serious
- 87.7% (typical: 85.6%)
- Drug's FAERS reports with a death
- 8.1% (typical: 15.9%)
Disease area and drugs
- Disease areas
- psychiatry
- Drugs matched to FDA substances
- oxytocin
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Oxytocin as Adjunctive Therapy for Schizophrenia NCT01699997 · started 2014 · scored riskier than 20% of active trials completed
- Oxytocin and Social Cognition in Schizophrenia NCT00884897 · started 2010 · scored riskier than 26% of active trials completed
- Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia NCT01394471 · started 2011 · scored riskier than 20% of active trials completed
- Effects of Oxytocin Nasal Spray on Social Affiliation NCT00663039 · started 2009 · scored riskier than 12% of active trials completed
- Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD) NCT01908205 · started 2013 · scored riskier than 24% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.